In vitro activities of aminoglycosides, lincosamides, and rifamycins against Mycobacterium leprae.
In vitro activities of aminoglycosides, lincosamides, and rifamycins against Mycobacterium leprae.
复制标题
氨基糖苷类、林可酰胺类和利福霉素对麻风分枝杆菌的体外活性。
DOI：
10.1128/aac.35.6.1232
复制
发表时间：
1991
影响因子：
4.9
通讯作者：
Franzblau,SG
中科院分区：
文献类型：
--
作者：
Franzblau,SG
用BACTEC 460系统评价了各种氨基糖苷类、林可酰胺类和利福霉素类药物对麻风分枝杆菌的体外活性。在20 μ g/ml时，庆大霉素、卡那霉素、妥布霉素、链霉素和阿米卡星无活性。林可霉素在20微克/毫升时有活性，克林霉素在0.31微克/毫升时有活性。利福霉素SV、利福昔单抗和利福平分别在3.1、3.1 - 12.5和200 ng/ml时具有活性。体外试验与M.抗微生物剂，氨基糖苷类药物除外。
The in vitro activities of a variety of aminoglycosides, lincosamides, and rifamycins against Mycobacterium leprae were evaluated with the BACTEC 460 system. At 20 micrograms/ml, gentamicin, kanamycin, tobramycin, streptomycin, and amikacin were inactive. Lincomycin was active at 20 micrograms/ml, and clindamycin was active at 0.31 micrograms/ml. Rifamycin SV, rifabutin, and rifampin were active at 3.1, 3.1 to 12.5, and 200 ng/ml, respectively. The in vitro assay correlates well with the in vivo response of M. leprae to antimicrobial agents, with the exception of the aminoglycosides.